Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – What’s Next?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.32 and traded as high as $3.89. Cumberland Pharmaceuticals shares last traded at $3.74, with a volume of 85,503 shares.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CPIX shares. Wall Street Zen raised shares of Cumberland Pharmaceuticals to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Down 0.3%

The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11. The company has a market capitalization of $55.95 million, a PE ratio of -15.58 and a beta of -0.53. The business’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $3.32.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.The firm had revenue of $8.29 million for the quarter.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Heron Bay Capital Management purchased a new stake in Cumberland Pharmaceuticals in the 2nd quarter valued at about $111,000. Two Sigma Investments LP increased its position in shares of Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after acquiring an additional 27,980 shares during the period. Bridgeway Capital Management LLC lifted its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth approximately $34,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.